Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Public ClinicalTrials.gov record NCT03657160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Study identification
- NCT ID
- NCT03657160
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Enrollment
- 343 participants
Conditions and interventions
Conditions
Interventions
- Vedolizumab Placebo Drug
- Vedolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2019
- Primary completion
- Feb 6, 2022
- Completion
- May 8, 2022
- Last update posted
- Jun 5, 2023
2019 – 2022
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294 | — |
| David Geffen School of Medicine at University of California Los Angeles | Los Angeles | California | 90095 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Augusta University Georgia Cancer Center | Augusta | Georgia | 30912 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kentucky Chandler Medical Center | Lexington | Kentucky | 40536 | — |
| Marlene and Stewart Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Cohen Children's Medical Center | New Hyde Park | New York | 11040 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| Columbia University Medical Center - The Columbia Center for Translational Immunology | New York | New York | 10032 | — |
| University of North Carolina Hospitals | Chapel Hill | North Carolina | 27514 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Massey Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 112 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03657160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03657160 live on ClinicalTrials.gov.